Results 71 to 80 of about 5,867,860 (378)

Heat shock proteins in multiple myeloma [PDF]

Oncotarget, 2014
Heat shock proteins are molecular chaperones with a central role in protein folding and cellular protein homeostasis. They also play major roles in the development of cancer and in recent years have emerged as promising therapeutic targets. In this review, we discuss the known molecular mechanisms of various heat shock protein families and their ...
Lei, Zhang, Jacqueline H L, Fok, Faith E, Davies   +2 more
openaire   +2 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. [PDF]

, 2007
Canonical Wnt signaling is an osteo-inductive signal that promotes bone repair through acceleration of osteogenic differentiation by progenitors. Dkk-1 is a secreted inhibitor of canonical Wnt signaling and thus inhibits osteogenesis.
Angela Smolarz, Carl Gregory, Darwin Prockop, Edwin Horwitz, Jacob Reiser, Najat Daw, Narae Lee, Odile David, Robert Kutner, Scott Olson   +9 more
core   +3 more sources

Improving the understanding and interpretation of myeloma screening among resident doctors and physician associates: a quality improvement project

Future Healthcare Journal
Introduction: Myeloma is the second most common blood cancer in the UK, with a median age at diagnosis of 72.6 years.1 Patients with myeloma can initially present with vague and non-specific symptoms, making early diagnosis challenging.
Mahmoud Gouda, Hannah Hunter
doaj   +1 more source

Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells

Haematologica, 2010
Background Multiple myeloma is a life-threatening disease and despite the introduction of stem cell transplantation and novel agents such as thalidomide, lenalidomide, and bortezomib most patients will relapse and develop chemoresistant disease ...
Djordje Atanackovic, York Hildebrandt, Adam Jadczak, Yanran Cao, Tim Luetkens, Sabrina Meyer, Sebastian Kobold, Katrin Bartels, Caroline Pabst, Nesrine Lajmi, Maja Gordic, Tanja Stahl, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kröger   +14 more
doaj   +1 more source

Prognostic value of plasmablastic morphology and p21, p53 and Cyclin D1 expression in myeloma cells: retrospective study of 122 patients with newly diagnosed multiple myeloma

Biotechnology & Biotechnological Equipment, 2021
Multiple myeloma (MM) is the most common bone marrow malignancy which is defined with bone marrow infiltration of more than 10% of terminally differentiated plasma cells sive myeloma cells.
Jurijs Nazarovs, Austra Breikša, Regīna Kleina, Sandra Lejniece, Jūlija Voicehovska, Georgi Momekov   +5 more
doaj   +1 more source

IMMUNOCHEMICAL STUDIES ON MOUSE MYELOMA PROTEINS REACTIVE WITH DEXTRANS OR WITH FRUCTOSANS AND ON HUMAN ANTILEVANS

Journal of Experimental Medicine, 1974
Four BALB/c IgA mouse myeloma proteins (W3129, W3434, QUPC 52, and UPC 102) reactive with dextran, four myeloma proteins reactive with fructosans, three IgA (W3082, UPC 61, and Y5476), and one IgG2a (UPC 10), and two human antilevans were studied ...
J. Cisar, E. Kabat, J. Liao, M. Potter
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing

Diagnostic Pathology, 2018
Background Plasma cell myeloma (PCM) is a neoplasm of terminally differentiated B lymphocytes with molecular heterogeneity. Although therapy-related myeloid neoplasms are common in plasma cell myeloma patients after chemotherapy, transdifferentiation of ...
Jonathon H. Gralewski, Ginell R. Post, Frits van Rhee, Youzhong Yuan   +3 more
doaj   +1 more source

INDIVIDUAL ANTIGENIC SPECIFICITY OF MYELOMA PROTEINS

Journal of Experimental Medicine, 1965
The specific antigenic structure of individual myeloma proteins was investigated for the presence of similar antigenic determinants in pooled γ-globulin and for the localization of these determinants on the γ-globulin molecules.
H. Grey, M. Mannik, H. Kunkel
semanticscholar   +1 more source